[Abstract Only] Meta-analysis: Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: PARP Inhibitors Linked With Blood Cancer Risk — Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden – MedPage Today

Commentary on Twitter

NEW research: a safety meta-analysis of RCTs and a retrospective study of the WHO pharmacovigilance database shows an increased risk of myelodysplastic syndrome and acute myeloid leukaemia in patients treated w/ PARP inhibitors #MDSsm #leusm https://t.co/evYF1ozg6c

— The Lancet Haematology (@TheLancetHaem) December 21, 2020